Bausch Health Companies (BHC) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bausch Health Companies (BHC) has outperformed Prestige Consumer Healthcare (PBH) over the past year, losing 4.7% versus a loss of 24.4%. Over five years, PBH leads with a -18.1% price change compared with -78.8% for BHC. Prestige Consumer Healthcare is the larger company by market cap ($2.30 billion vs $2.27 billion), about 1.0 times the size, while Bausch Health Companies is growing revenue faster (+6.7% vs -4.3%).
On valuation, Bausch Health Companies trades at a lower forward P/E (1.5x vs 9.6x for Prestige Consumer Healthcare). Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus 1.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | PBH |
|---|---|---|
| Share price | $6.08 | $48.62 |
| Market cap | $2.27B | $2.30B |
| 1-day change | +0.66% | +1.57% |
| YTD return | -13.09% | -22.40% |
| 1-year return | -4.73% | -24.36% |
| 5-year return | -78.80% | -18.06% |
| P/E ratio (TTM) | — | 13.62 |
| Forward P/E | 1.45 | 9.57 |
| EPS (TTM) | $-2.95 | $3.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.27B | $1.09B |
| Revenue growth (YoY) | +6.66% | -4.31% |
| Net income (latest FY) | $157.00M | $190.30M |
| Gross margin | — | 54.71% |
| Operating margin | 17.66% | 28.42% |
| Net margin | 1.53% | 17.48% |
| 52-week high | $8.00 | $71.07 |
| 52-week low | $4.33 | $42.62 |
| Distance from 52-week high | -24.00% | -31.59% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +23.36% | +39.45% |
| Average volume | 3.24M | 547.31K |
| Shares outstanding | 373.99M | 47.37M |
| Employees | 20,300 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHC has outperformed PBH by 19.6 percentage points over the past year.
- Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus 1.5 cents for Bausch Health Companies.
- Bausch Health Companies grew revenue faster in its latest fiscal year (+6.66% vs -4.31%).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
BHC vs PBH FAQ
Which is bigger, Bausch Health Companies or Prestige Consumer Healthcare?
Prestige Consumer Healthcare (PBH) is larger, with a market capitalization of $2.30B compared with $2.27B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or PBH?
BHC returned -4.73% over the past 12 months, compared with -24.36% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.